KALV - CIK 0001348911
KalVista Pharmaceuticals, Inc. (KALV) reported net income of -$183.40M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$183.40M | -44.9% |
| FY 2024 | -$126.60M | -36.3% |
| FY 2023 | -$92.90M | -12.8% |
| FY 2022 | -$82.34M | -78.1% |
| FY 2021 | -$46.24M | -58.8% |
| FY 2020 | -$29.12M | -39.9% |
| FY 2019 | -$20.82M | -31.7% |
| FY 2018 | -$15.80M | +15.0% |
| FY 2017 |
KalVista Pharmaceuticals, Inc. (KALV) reported net income of -$183.40M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, KalVista Pharmaceuticals, Inc.'s net income declined from -$5.68M to -$183.40M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$18.60M |
| +25.1% |
| FY 2015 | -$24.85M | -86.0% |
| FY 2014 | -$13.36M | -135.3% |
| FY 2013 | -$5.68M | - |